Drug updated on 10/28/2024
| Dosage Form | Injection (intravenous; 400 mg lyophilized powder in a single-dose vial) |
| Drug Class | Zaire ebolavirus glycoprotein (EBOV GP)-directed human monoclonal antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Ebanga (ansuvimab-zykl) demonstrated efficacy in reducing mortality in Ebola virus disease (EVD) patients, with a mortality rate of 35.1% when administered as a 50 mg/kg single IV (intravenous) dose.
- Compared to other treatments, Ebanga is less effective than ZMapp, which showed a standard of care efficacy of 91.2%, and Inmazeb, which reduced mortality by 17%.
- The study does not provide any specific information on differences in effectiveness among various population types or subgroups.
- The common adverse effects associated with Ebanga (ansuvimab-zykl) include fever, tachycardia, diarrhea, vomiting, hypotension, tachypnea, and chills, similar to those observed with other Ebola virus disease treatments.
- The study does not report any significant safety concerns specific to particular population subgroups or any detailed comparison of safety profiles between Ebanga, ZMapp, and Inmazeb.
- The study notes that Ebanga (ansuvimab-zykl) may be particularly suitable for patients with cardiovascular complications, though no further details on population types or subgroups are provided.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ebanga (ansuvimab-zykl) Prescribing Information. | 2022 | Ridgeback Biotherapeutics., LP, Miami, FL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020 | 2022 | Journal of Infection and Public Health |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Therapeutics for Ebola virus disease | 2022 | World Health Organization |